

CONSIDERATION OF POLICY OPTIONS FOR USE OF PNEUMOCOCCAL VACCINES

**ACIP PNEUMOCOCCAL VACCINES
WORKING GROUP**

October 22-23, 2008

Pneumococcal vaccines working group

- **ACIP members:**
 - S. Michael Marcy (chair, 6/08)
 - Dale Morse
 - Kathy Neuzil
- **Liaison representatives:**
 - Nancy Bennett, NACCHO
 - Rick Zimmerman, Univ of Pittsburgh
 - Lorry Rubin, AAP/COID
 - William Schaffner, NFID
- **Ex Officio members:**
 - Lucia Lee, FDA
 - Kristin Nichol, VA
 - Ray Strikas, NVPO
- **Consultants:**
 - Jay Butler, Alaska DPH
 - Lisa Jackson, Group Health, WA
 - Julie Morita, Chicago Dept of PH
 - Farukh Khambaty, NIH/NIAID
 - Kate O'Brien, Johns Hopkins Univ
- **CDC**
 - William Atkinson
 - Angela Calugar
 - Tom Hennessy
 - Jessica Henry
 - Beth Hibbs
 - Matt Moore
 - Gina Mootrey
 - Pekka Nuorti
 - Jennifer Rosen
 - Sandy Steiner
 - Cynthia Whitney

TOPICS UNDER REVIEW BY PNEUMOCOCCAL VACCINE WG

- Expand PPSV23* target groups to include persons 19-64 years of age who are cigarette smokers

* Pneumococcal polysaccharide 23-valent vaccine

† Pneumococcal conjugate 7-valent vaccine

TOPICS UNDER REVIEW BY PNEUMOCOCCAL VACCINE WG

- Expand PPSV23* target groups to include persons 19-64 years of age who are cigarette smokers
- Use of PPSV23 after PCV7† for AI/AN children 24 through 59 months of age
Use of PPSV23 for AI/AN persons younger than 65 years of age

* Pneumococcal polysaccharide 23-valent vaccine

† Pneumococcal conjugate 7-valent vaccine

PNEUMOCOCCAL VACCINES WORKING GROUP AI/AN CONSULTANTS

Indian Health Service

Amy Groom, MPH, Immunization Program Manager

Steve Holve, MD, Chief Clinical Consultant, Pediatrics

Alaska Native Tribal Health Consortium

Ros Singleton, MD, MPH, Immunization Consultant

Johns Hopkins Center for American Indian Health

Kate O'Brien, MD, MPH, Associate Professor

CDC Arctic Investigations Program

Tom Hennessy, MD, MPH, Director

Jay Wenger, MD, Associate Director for Science

TOPICS UNDER REVIEW BY PNEUMOCOCCAL VACCINE WG

- Expand PPSV23* target groups to include persons 19-64 years of age who are cigarette smokers
- Use of PPSV23 after PCV7† for AI/AN children 24 through 59 months of age
Use of PPSV23 for AI/AN persons younger than 65 years of age
- Interval for revaccination with PPSV23 for persons >2 years of age who are immunocompromised, who have sickle cell disease, anatomic or functional asplenia

* Pneumococcal polysaccharide 23-valent vaccine

† Pneumococcal conjugate 7-valent vaccine

MAJOR CONSIDERATIONS IN REVIEWING PROPOSED RECOMMENDATIONS

- Burden of disease
- Vaccine effectiveness
 - short-term
 - long-term
- Vaccine safety
 - adverse events
 - hypo-responsiveness (PPSV23)
- Feasibility of implementation
- Cost effectiveness
- Status of PCV13